Hipoglikemia Neonatus

01Pathophysiology

Neonatal hypoglycemia results from an imbalance between glucose supply and glucose consumption during the critical transition from intrauterine to extrauterine life. In utero, the fetus receives a continuous transplacental glucose supply and does not need to regulate its own blood sugar. At birth, this supply is abruptly severed, and the neonate must mobilize hepatic glycogen stores and initiate gluconeogenesis to maintain euglycemia. When these mechanisms are insufficient or overwhelmed, hypoglycemia develops.

The single most tested mechanism involves the infant of a diabetic mother (IDM). During pregnancy, maternal hyperglycemia drives excess glucose across the placenta, which stimulates fetal pancreatic beta-cell hyperplasia and hyperinsulinism. After delivery, the maternal glucose supply stops, but the neonate's insulin levels remain inappropriately elevated. This transient hyperinsulinemic state causes rapid glucose consumption and suppresses compensatory glycogenolysis and lipolysis, leading to profound hypoglycemia within the first 1 to 2 hours of life. The same hyperinsulinism explains why these infants are macrosomic: insulin acts as a potent fetal growth factor.

In contrast, SGA and premature infants develop hypoglycemia through a different pathway. These neonates have inadequate hepatic glycogen reserves because glycogen deposition occurs primarily in the third trimester. They also have reduced subcutaneous fat, limiting their ability to generate ketone bodies as an alternative fuel. Their relatively large brain-to-body ratio means proportionally higher glucose demand with limited stores.

A third category involves increased glucose utilization without hyperinsulinism. Conditions such as neonatal sepsis, perinatal asphyxia, hypothermia, and polycythemia all increase metabolic demand and can deplete glucose rapidly even in an otherwise healthy newborn.

The brain is the organ most vulnerable to hypoglycemia because it depends almost exclusively on glucose as its energy substrate in the neonatal period. Prolonged or severe hypoglycemia can cause permanent neuronal injury, particularly in the occipital cortex, leading to long-term neurodevelopmental impairment. This is why early detection and treatment are so heavily emphasized.

02Classification and Clinical Manifestation

Classification By Mechanism

A critical exam concept: jitteriness is the most common presenting sign, but it must be distinguished from neonatal seizures. Jitteriness is stimulus-sensitive, can be stopped by passive flexion of the affected limb, and is not accompanied by abnormal eye movements. Seizures are stimulus-independent, cannot be suppressed by restraint, and may involve eye deviation or rhythmic movements.

03Diagnostic Workup

The best initial test is always a point-of-care glucose obtained via heel stick. This is done as part of routine screening for all at-risk neonates (IDM, LGA, SGA, preterm) within the first 1 to 2 hours after birth and before feeds. The operational threshold for intervention is a plasma glucose below 45 mg/dL, though some guidelines use tiered thresholds in the first 4 hours versus 4 to 24 hours of life.

If the bedside value is low, it should be confirmed with a serum plasma glucose sent to the laboratory, but treatment should never be delayed waiting for lab confirmation in a symptomatic infant. The point-of-care reading may underestimate or overestimate true plasma glucose by 10 to 15 mg/dL, which is why confirmation matters for borderline values.

When hypoglycemia is persistent (lasting beyond 48 to 72 hours) or refractory to standard glucose infusion rates, the next step is to obtain a critical sample at the time of documented low glucose. The most important value in this panel is insulin. If insulin is inappropriately elevated during hypoglycemia (with suppressed beta-hydroxybutyrate and free fatty acids), the diagnosis is hyperinsulinism. In hyperinsulinism, the neonate fails to mount a ketogenic response because insulin suppresses both lipolysis and ketogenesis. This biochemical pattern (hypoketotic, hypofattyacidemic hypoglycemia with detectable insulin) is pathognomonic.

If cortisol and growth hormone are low during hypoglycemia, consider hypopituitarism or adrenal insufficiency. Elevated urine organic acids or abnormal acylcarnitine profiles point toward inborn errors of metabolism such as fatty acid oxidation defects or glycogen storage diseases.

04Management and Treatment

Acute stabilization begins with recognizing that any symptomatic neonate must receive intravenous dextrose regardless of the glucose value. The standard bolus is D10W at 2 mL/kg, which delivers 200 mg/kg of glucose. This is followed immediately by a continuous glucose infusion (GIR) starting at 6 to 8 mg/kg/min. Avoid using D25W or D50W in neonates because hyperosmolar dextrose solutions can cause rebound hyperinsulinemia and increase the risk of intraventricular hemorrhage, particularly in preterm infants.

The glucose infusion rate is calculated using the formula:

$$GIR(mg\mathrm{/}kg\mathrm{/}min)=\frac{IVrate(mL\mathrm{/}hr)\times Dextroseconcentration(\mathrm{\%})\times 10}{60\times Weight(kg)}GIR\backslash \; (mg/kg/min)\; =\; \backslash frac\{IV\backslash \; rate\backslash \; (mL/hr)\; \backslash times\; Dextrose\backslash \; concentration\backslash \; (\backslash \%)\; \backslash times\; 10\}\{60\; \backslash times\; Weight\backslash \; (kg)\}$$After initiating the infusion, glucose should be rechecked every 30 to 60 minutes until stable, and the GIR should be titrated upward in increments of 1 to 2 mg/kg/min if hypoglycemia persists. If the infant requires a GIR exceeding 12 mg/kg/min to maintain euglycemia, this strongly suggests persistent hyperinsulinism and warrants further etiologic workup and pharmacologic intervention.

For asymptomatic at-risk neonates, the first-line approach is early and frequent enteral feeding (breast milk or formula) within the first hour of life. Glucose is rechecked 30 minutes after feeding. If the glucose normalizes and the infant is feeding well, continue routine monitoring per protocol. If glucose fails to rise above threshold after two consecutive feeds, escalate to IV dextrose.

Diazoxide is the first-line pharmacologic agent for persistent hyperinsulinism. It works by opening potassium-ATP channels on pancreatic beta cells, thereby inhibiting insulin secretion. Side effects include fluid retention, hypertrichosis, and rarely hyperuricemia. Glucagon can be used as a temporizing measure while IV access is being established; it stimulates hepatic glycogenolysis but is only effective if glycogen stores are adequate. Octreotide (a somatostatin analog) is second-line for hyperinsulinism refractory to diazoxide.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common mistake students make with neonatal hypoglycemia is treating the question as a glucose number rather than a clinical scenario. Test-writers will present a symptomatic neonate and expect you to initiate IV dextrose immediately, not oral feeds. The trap is choosing "feed the baby and recheck" for a neonate who is seizing, apneic, or severely lethargic. Oral or enteral feeding is appropriate only for asymptomatic infants with borderline glucose values.

A second classic trap involves the infant of a diabetic mother who presents with jitteriness at 1 hour of life. Students may overthink and choose hypocalcemia or sepsis workup. The timing is the giveaway: hypoglycemia in an IDM occurs in the first 1 to 2 hours because of residual hyperinsulinism, while hypocalcemia typically manifests between 24 to 72 hours.

Another high-yield pearl: if a vignette describes a neonate requiring glucose infusion rates above 12 mg/kg/min and hypoglycemia is still not correcting, the answer is not "increase the infusion further." The answer is to suspect persistent hyperinsulinism and order a critical sample (insulin, C-peptide, beta-hydroxybutyrate). The next step in management at that point is diazoxide, not more dextrose.

Never use D50W or D25W in a neonate. This is a deliberately placed distractor. The correct concentration is always D10W at 2 mL/kg for the initial bolus.

Finally, remember that Beckwith-Wiedemann syndrome is the genetic mimic of IDM. Both produce macrosomic, hypoglycemic neonates. The discriminator is the physical exam: macroglossia plus omphalocele plus ear anomalies point to Beckwith-Wiedemann, and the hyperinsulinism in this condition is persistent, requiring long-term management rather than simple observation.